Aurora Kinase
The Aurora kinases comprise a family of evolutionary conserved serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C). Aurora kinases control multiple events during cell cycle progression and are essential for mitotic and meiotic bipolar spindle assembly and function.
Aurora-A, Aurora-B, and Aurora-C share a highly conserved kinase domain but have quite different subcellular localizations and functions during mitosis. Aurora-A mostly controls centrosome maturation and bipolar spindle assembly, while Aurora-B and Aurora-C are required for condensation, attachment to kinetochores, and alignment of chromosomes during (pro-)metaphase and cytokinesis. In human tumors, all Aurora kinase members play oncogenic roles related to their mitotic activity and promote cancer cell survival and proliferation. Inhibitors targeting Aurora kinases have attracted attention in cancer research.
Aurora Kinase Isoform Specific Products
All Product Categories
-
Aurora Kinase Related Products (232)
Related Products (232)
-
Antibodies (4)
-
Aurora Kinase Isoform Comparison
-
Butrin
0 ImagesButrin is a compound found in Butea monosperma flowers. Butrin reduces expression of SIRT1, AURKB, cyclin D1, pAKT, GSK-3β, β-catenin, and TGF-3β expression, enhances apoptosis and ROS production in cancer cells. Butrin downregulates Wnt and NF-κB signaling, mitigates oxidative stress, reduces proinflammatory cytokine (TNF-α, IL-6 and IL-8) production and suppresses neuroinflammation. Butrin inhibits IKK enzyme activity. Butrin can be used for the researches of colorectal cancer, Alzheimer’s disease, and rheumatoid arthritis.
-
Aurora kinase-IN-2
0 ImagesCat. No.: HY-150592CAS No.: 2241914-86-1Aurora kinase-IN-2 (compound 12Aj) is a potent Aurora kinase inhibitor with IC50 values of 90 and 152 nM for Aurora A and Aurora B. Aurora kinase-IN-2 arrests cell cycle at G2/M phase by regulating cyclin B1 and cdc2. Aurora kinase-IN-2 can be used for cancer research.
-
Aurora A inhibitor 1
0 ImagesCat. No.: HY-143713CAS No.: 2677799-04-9Aurora A inhibitor 1 is a potent and selective inhibitor of Aurora A. Aurora A has been implicated in cancers of diverse histological origin and may possess oncogenic properties when overexpressed. Aurora A inhibitor 1 has the potential for the research of cancer diseases mediated by aurora a (extracted from patent WO2021147974A1, compound 49).
-
Aurora kinase inhibitor-9
0 ImagesCat. No.: HY-147703CAS No.: 2419107-09-6Aurora kinase inhibitor-9 (compound 9d) is a potent AURKA/B dual aurora kinase inhibitor with IC50s of 0.093, 0.09 µM for Aurora A, Aurora B, respectively. Aurora kinase inhibitor-9 shows broad spectrum anti-proliferative activity.
-
Aurkb Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS01272Aurkb Rat Pre-designed siRNA Set A contains three designed siRNAs for Aurkb gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Aurka Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS01267Aurka Mouse Pre-designed siRNA Set A contains three designed siRNAs for Aurka gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
CDK1-IN-9
0 ImagesCat. No.: HY-182752CDK1-IN-9 is an orally active and selective CDK1 inhibitor with an IC50 of 5.5 nM. CDK1-IN-9 exhibits broad antiproliferative activity, particularly against HCT116 colon cancer cells. CDK1-IN-9 induces G2/M phase arrest and downregulates CDK1, cyclin B1, and the replication initiation factor CDC45. CDK1-IN-9 induces severe DNA replication stress, subsequently activating the p53 signaling pathway to trigger apoptosis. CDK1-IN-9 can be used for research on colon cancer, liver cancer and gastric cancer.
-
BRD-7880
0 ImagesCat. No.: HY-123610CAS No.: 1456542-69-0BRD-7880 is a potent and highly specific inhibitor of Aurora Kinase B (AURKB) and Aurora Kinase C (AURKC), with IC50 values of 7 nM and 12 nM, respectively.
-
AURKA-IN-3
0 ImagesCat. No.: HY-175982AURKA-IN-3 (Compound AL8) is an irreversible covalent Aurora kinase A (AURKA) inhibitor with an IC50 value of 23.0 nM. AURKA-IN-3 inhibits the activation of cAMP signaling pathway and phospholipase C (PLC) signaling pathway mediated by AURKA, and reduces the autophosphorylation level of AURKA. AURKA-IN-3 is promising for research of malignant tumors associated with high AURKA expression (e.g., leukemia, lymphoma).
-
LY3295668 erbumine
0 ImagesCat. No.: HY-114258ACAS No.: 1919888-07-5Synonyms: AK-01 erbumineLY3295668 (AK-01) erbumine is a highly specific and orally active inhibitor of Aurora-A kinase with a Ki values for AurA and AurB of 0.8 nM and 1038 nM respectively. LY3295668 erbumine can effectively inhibit the autophosphorylation of AurA, induce mitotic arrest and apoptosis. LY3295668 erbumine avoids the formation of polyploids related to AurB inhibition. LY3295668 erbumine can be used for the study of small cell lung cancer.
-
MK-5108-NH-PEG2-alkyne
0 ImagesCat. No.: HY-175827MK-5108-NH-PEG2-alkyne is a Aurora kinase A (AURKA) inhibitor. MK-5108-NH-PEG2-alkyne can be used for synthesis of PROTAC AURKA degrader 1 (HY-175830).
-
HOI-07
0 ImagesCat. No.: HY-125158CAS No.: 1451013-67-4HOI-07 is a selective Aurora B kinase inhibitor. HOI-07 blocks phosphorylation of histone H3 on Ser10 in lung cancer cells. HOI-07 induces cell-cycle arrest, and apoptosis. HOI-07 has antitumor activity, and suppresses the tumor growth of A549, 143B and KHOS xenografts.
-
Aurka Rat Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS01268Aurka Rat Pre-designed siRNA Set A contains three designed siRNAs for Aurka gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
SAR156497
0 ImagesCat. No.: HY-12476CAS No.: 1256137-14-0SAR156497 (compound 47) is an Aurora inhibitor, with IC50 values of 0.6 nM and 1 nM for Aurora A and Aurora B, respectively. SAR156497 can also inhibit PDE3, with IC50 value of 4 μM. SAR156497 can be used in anticancer research.
-
KW-2450 free base
0 ImagesCat. No.: HY-167854CAS No.: 904899-25-8KW-2450 Free base is a potent multikinase inhibitor targeting Aurora A and B kinases, demonstrating significant antitumor activity against triple-negative breast cancer (TNBC). KW-2450 Free base effectively reduces cell viability, promotes apoptosis, and inhibits colony formation and mammosphere formation in TNBC cells. KW-2450 Free base significantly suppresses the growth of TNBC xenografts, leading to tetraploid accumulation followed by apoptosis or the survival of octaploid cells. KW-2450 Free base enhances the efficacy of combination therapy with the MEK inhibitor selumetinib, resulting in a synergistic antitumor effect in TNBC models. KW-2450 Free base also acts as an orally bioavailable inhibitor of IGF-1R and IR tyrosine kinases, contributing to its potential antineoplastic activity by inhibiting tumor cell proliferation and inducing apoptosis.
-
TAK-901 hydrochloride
0 ImagesCat. No.: HY-12201ACAS No.: 934542-50-4TAK-901 hydrochloride is a multi-targeted aurora inhibitor with IC50s of 21 and 15 nM for aurora A and B, respectively.
-
JNJ-7706621 (Standard)
0 ImagesCat. No.: HY-10329RCAS No.: 443797-96-4JNJ-7706621 (Standard) is the analytical standard of JNJ-7706621 (HY-10329). This product is intended for research and analytical applications. JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B, respectively.
-
AJI-214
0 ImagesCat. No.: HY-164455CAS No.: 1395886-20-0AJI-214 is a dual-target inhibitor of Aurora kinase A and JAK2. AJI-214 directly blocks Aurora kinase A to inhibit T cell mitotic progression and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-214 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD).
-
SCH-1473759 (Standard)
0 ImagesCat. No.: HY-10482RCAS No.: 1094069-99-4SCH-1473759 (Standard) is the analytical standard of SCH-1473759 (HY-10482). This product is intended for research and analytical applications. SCH-1473759 is an aurora inhibitor with IC50s of 4 and 13 nM for aurora A and B, respectively.
-
MLN8054 (Standard)
0 ImagesCat. No.: HY-10180RCAS No.: 869363-13-3MLN8054 (Standard) is the analytical standard of MLN8054. This product is intended for research and analytical applications. MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.
